Literature DB >> 11503953

Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics.

C Aul1, A Giagounidis2, U Germing2.   

Abstract

Although myelodysplastic syndromes (MDS) have been increasingly diagnosed in recent years, precise data on their prevalence and incidence are still lacking. Due to difficulties of diagnosis and classification, large-scale population-based studies that are required for obtaining truly representative data on the epidemiology of MDS are currently not available. Our present knowledge of the incidence and other epidemiological characteristics of MDS is based on a few regional studies performed by authors with a long-lasting interest in these hemopathies. Despite certain limitations, these studies have consistently shown that MDS are relatively common hematological malignancies. Their crude incidence varies from 2.1 to 12.6 cases per 100,000 people per year. Among the age group that is mainly affected, people older than 70 years, we are now faced with incidence rates of about 15 to 50 cases per 100,000 people per year. The recent increase in MDS incidence observed in some studies is probably not the result of an actual increase in the number of cases, but reflects improvements in geriatric medical care and diagnosis.

Entities:  

Mesh:

Year:  2001        PMID: 11503953     DOI: 10.1007/BF02994001

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  42 in total

1.  Preleukemia. The hematologic syndrome preceding acute leukemia.

Authors:  M I Saarni; J W Linman
Journal:  Am J Med       Date:  1973-07       Impact factor: 4.965

Review 2.  The 5q-anomaly.

Authors:  H Van den Berghe; K Vermaelen; C Mecucci; D Barbieri; G Tricot
Journal:  Cancer Genet Cytogenet       Date:  1985-07

3.  The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution.

Authors:  I Cunningham; S J MacCallum; M D Nicholls; K Byth; J W Hewson; B Arnold; P I Motum; S P Mulligan; G G Crane
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

Review 4.  Epidemiologic perspectives on myelodysplastic syndromes and leukemia.

Authors:  P Cole; W Sateren; E Delzell
Journal:  Leuk Res       Date:  1995-06       Impact factor: 3.156

5.  Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare.

Authors:  S Oguma; Y Yoshida; H Uchino; T Maekawa; T Nomura; H Mizoguchi
Journal:  Leuk Res       Date:  1995-03       Impact factor: 3.156

6.  Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases.

Authors:  S K Juneja; M Imbert; H Jouault; J Y Scoazec; F Sigaux; C Sultan
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

7.  Prevalence of the myelodysplastic syndromes in Japan.

Authors:  H Shimizu; Y Matsushita; K Aoki; T Nomura; Y Yoshida; H Mizoguchi
Journal:  Int J Hematol       Date:  1995-01       Impact factor: 2.490

8.  Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study.

Authors:  C Nisse; C Lorthois; V Dorp; E Eloy; J M Haguenoer; P Fenaux
Journal:  Leukemia       Date:  1995-04       Impact factor: 11.528

9.  Incidence of myelodysplastic syndromes in a Swedish population.

Authors:  A Rådlund; T Thiede; S Hansen; M Carlsson; L Engquist
Journal:  Eur J Haematol       Date:  1995-03       Impact factor: 2.997

10.  Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.

Authors:  C Aul; N Gattermann; W Schneider
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

View more
  27 in total

Review 1.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 2.  Thrombocytopenia in patients with myelodysplastic syndromes.

Authors:  Jeffrey Bryan; Elias Jabbour; Hillary Prescott; Hagop Kantarjian
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

Review 3.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.

Authors:  Esther N Oliva; Carina Schey; Adam S Hutchings
Journal:  Am J Blood Res       Date:  2011-09-10

Review 5.  Deferasirox for managing iron overload in people with myelodysplastic syndrome.

Authors:  Joerg J Meerpohl; Lisa K Schell; Gerta Rücker; Nigel Fleeman; Edith Motschall; Charlotte M Niemeyer; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2014-10-28

6.  The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Authors:  Michaela Cada; Catherin I Segbefia; Robert Klaassen; Conrad V Fernandez; Rochelle A Yanofsky; John Wu; Yves Pastore; Mariana Silva; Jeffrey H Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark Belletrutti; Vicky Breakey; Lawrence Jardine; Lisa Goodyear; Lillian Sung; Mary Shago; Joseph Beyene; Preeti Sharma; Bozana Zlateska; Yigal Dror
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 7.  Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Authors:  Katja Sockel; Uwe Platzbecker
Journal:  Drugs       Date:  2018-12       Impact factor: 9.546

8.  Myelodysplastic syndrome: An update on diagnosis and therapy.

Authors:  Ahrin Koppel; Gary Schiller
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 9.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

Review 10.  Myelodysplastic syndrome: an update on diagnosis and therapy.

Authors:  Ahrin Koppel; Gary Schiller
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.